Prize winners of the Poster Session CHFR 2017
The 15th Annual CHFR Symposium took place at Holmenkollen Park Hotel, Oslo. More than 70 poster presenters contributed with recent advances in basic and clinical heart research.
Click to see the Prize winners of the Poster Session
Thank you to all participants, and invited Speakers:
Key note by Calum A. MacRae, Brigham and Women’s Hospital and Harvard Medical School. Other speakers:
Anthony Rosenzweig, Harvard Medical School, USA.
Burkert Pieske, Charité Universitätsmedizin Berlin and Deutsches Herzzentrum Berlin.
Carolyn Lam, National Heart Centre Singapore.
Dan Roden, Vanderbilt University Medical Center, USA.
James L Januzzi, Massachusetts General Hospital and Harvard Research Clinical Institute, USA.
Julia Gorelik, Imperial College London, UK.
Leon Axel, NYU Langhorne Medical Center, USA
Ole M. Sejersted, University of Oslo and Oslo University Hospital
Peter Libby, Brigham and Women's Hospital, Harvard Med. School, USA.
Stefan Engelhardt, Technische Universität München.
Sumanth D. Prabhu, University of Alabama, USA.
Hot Topics: Protein phosphatase 1c associated with the cardiac sodium calcium exchanger 1 (NCX1) regulates its activity by dephosphorylating serine 68-phosphorylated phospholemman
NCX1, an important regulator of intracellular Ca2+ homeostasis, is a substrate-specifying PP1c-targeting protein. Using a variety of molecular techniques, this study demonstrates that cardiac NCX1 facilitating its own regulation by mediating dephosphorylation of pSer-68-phospholemman.
Read more in Journal of Biological Chemistry
Hot Topics: NT-proBNP levels improve risk assessment for poor outcome in patients with out-of-hospital cardiac arrest
NT-proBNP levels measured 24 hrs after out-of-hospital cardiac arrest predicted mortality and poor neurological outcome after one year on top of established risk indices.
Read more in Resuscitation
Hot Topics: Tocilizumab attenuated the inflammatory response and primarily PCI-related TnT release in NSTEMI patients
In a double-blind, placebo-controlled trial including 117 patients with NSTEMI, the IL-6 receptor antagonist tocilizumab administered as a single dose prior to coronary angiography reduced the levels of CRP and troponin-T.
Read more in European Heart Journal
